169 related articles for article (PubMed ID: 34763587)
1. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
Tarride JE; Husain M; Andersen A; Gundgaard J; Luckevich M; Mark T; Wagner L; Pieber TR
J Med Econ; 2021; 24(1):1318-1326. PubMed ID: 34763587
[TBL] [Abstract][Full Text] [Related]
2. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
[TBL] [Abstract][Full Text] [Related]
3. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
4. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
[TBL] [Abstract][Full Text] [Related]
5. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
Pratley RE; Emerson SS; Franek E; Gilbert MP; Marso SP; McGuire DK; Pieber TR; Zinman B; Hansen CT; Hansen MV; Mark T; Moses AC; Buse JB;
Diabetes Obes Metab; 2019 Jul; 21(7):1625-1633. PubMed ID: 30850995
[TBL] [Abstract][Full Text] [Related]
7. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
9. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.
Pollock RF; Valentine WJ; Marso SP; Gundgaard J; Hallén N; Hansen LL; Tutkunkardas D; Buse JB;
Diabetes Ther; 2018 Jun; 9(3):1217-1232. PubMed ID: 29713962
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
11. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.
Bilal A; Pratley RE
Curr Diab Rep; 2018 Sep; 18(11):102. PubMed ID: 30229352
[TBL] [Abstract][Full Text] [Related]
13. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
14. Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.
Galindo RJ; Pasquel FJ; Vellanki P; Alicic R; Lam DW; Fayfman M; Migdal AL; Davis GM; Cardona S; Urrutia MA; Perez-Guzman C; Zamudio-Coronado KW; Peng L; Tuttle KR; Umpierrez GE
Diabetes Obes Metab; 2022 Jan; 24(1):42-49. PubMed ID: 34490700
[TBL] [Abstract][Full Text] [Related]
15. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
16. Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.
Jensen MH; Hejlesen O; Vestergaard P
Diabetes Metab Res Rev; 2020 Jan; 36(1):e3225. PubMed ID: 31647163
[TBL] [Abstract][Full Text] [Related]
17. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
[TBL] [Abstract][Full Text] [Related]
18. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
19. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
Philis-Tsimikas A; Lane W; Pedersen-Bjergaard U; Wysham C; Bardtrum L; Harring S; Heller S
Diabetes Obes Metab; 2020 May; 22(5):779-787. PubMed ID: 31903697
[TBL] [Abstract][Full Text] [Related]
20. Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.
Alexopoulos AS; Andersen A; Donatsky AM; Gowda A; Buse JB
Diabetes Obes Metab; 2021 Aug; 23(8):1983-1988. PubMed ID: 33830626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
